Johnson & Johnson acquires Yellow Jersey Therapeutics for $1.25bn and gains global rights to NM26 for atopic dermatitis treatment.
Johnson & Johnson acquires Yellow Jersey Therapeutics, a subsidiary of Numab Therapeutics, for $1.25bn. The acquisition grants J&J global rights to NM26, an experimental Phase 2-ready bi-specific antibody for atopic dermatitis treatment. This follows J&J's recent acquisition of Proteologix for atopic dermatitis treatments. The deal is expected to close in H2 2024, subject to regulatory clearances.
May 28, 2024
5 Articles